Traditionally, the approach to addressing obesity has primarily centered on lifestyle modifications. However, it’s important to recognize that evidence indicates that attempts to manage weight through diet and exercise can be challenging due to physiological mechanisms. It is evident that obesity is a complex metabolic disease, and the path to achieving a lower weight can be difficult.
Excess weight can lead to several health issues, such as cardiovascular disease and type 2 diabetes, and it also imposes a significant financial burden while contributing to illness and death. Tirzepatide has shown positive effects in various areas and considerable weight loss and may improve the overall health outcomes for individuals with obesity. It reduces the risk of developing conditions like type 2 diabetes, reverses prediabetes, and cardiovascular disease, decreasing the need for multiple medications.
Overweight participants, some with prediabetes, reported clinically significant weight reduction and prediabetes reversal. Tirzepatide, with its dual GIP/GLP-1 action, shows the potential to outperform other GLP-1s like Semaglutide for the same indications. It helps prevent not only Type 2 Diabetes and Fatty Liver diseases but also other Metabolic Disorders. This includes reductions in waist circumference, systolic blood pressure, fasting insulin, lipid levels, and a percentage change in total body fat mass. Additional trials are essential to advance our understanding of the health benefits of Tirzepatide and other weight loss drugs.
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., … & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
Muzurović, E. M., Volčanšek, Š., Tomšić, K. Z., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022). Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver disease—current evidence. Journal of Cardiovascular Pharmacology and Therapeutics, 27, 10742484221146371
